Serotype-Specific Pneumococcal Antibodies in Breast Milk of Gambian Women Immunized With a Pneumococcal Polysaccharide Vaccine During Pregnancy

Background: In breast-feeding populations, immunization during pregnancy with pneumococcal polysaccharide offers a potentially useful approach to preventing pneumococcal disease in young infants. Methods: Breast milk samples were collected at 0, 2, 4 and 6 months after delivery from Gambian women vaccinated during pregnancy (24–32 weeks gestation) with Pneumovax II (n = 56) or Mengivax A&C (n = 57). Specimens were examined for secretory immunoglobulin A (s-IgA) concentration, subclass distribution and avidity specific to pneumococcal serotypes 4, 6B, 14, 19F and 23F and the antigen mixture in Pneumovax II by enzyme-linked immunosorbent assay. Colostral s-IgA and IgG concentrations in paired maternal sera were compared. Results: Colostral s-IgA concentrations specific to all pneumococcal polysaccharide antigens investigated were significantly higher (P < 0.05) among Pneumovax II vaccinees. Titers specific to serotypes 4, 6B and 14 and the vaccine formula remained significantly higher during 6 months, and those for 19F were higher during 4 months. Significantly higher concentrations of vaccine antigen-specific s-IgA antibody were sustained for 6 months after delivery (P = 0.011). Comparison of colostral s-IgA and IgG in serum revealed a significant correlation only among Mengivax A&C vaccinees for pneumococcal polysaccharide 23F (rs= 0.68; P ≤ 0.0001). Vaccination elicited trends toward increased s-IgA2, reaching significance for serotype 14 and the vaccine formula. Immunization elicited significantly higher s-IgA avidities specific to all pneumococcal polysaccharide antigens studied during 6 months. Conclusions: The public health value of immunization during pregnancy with pneumococcal polysaccharide vaccine in breast-feeding populations warrants further evaluation, particularly in populations with a high incidence of pneumococcal disease in early infancy.

[1]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[2]  K. O'Brien,et al.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial , 2003, The Lancet.

[3]  P. Brandtzaeg.  Mucosal immunity: integration between mother and the breast-fed infant. , 2003, Vaccine.

[4]  Ron Dagan,et al.  The potential indirect effect of conjugate pneumococcal vaccines. , 2003, Vaccine.

[5]  S. Obaro,et al.  Vaccines for children: policies, politics and poverty. , 2003, Vaccine.

[6]  J. Weiser,et al.  Antibody-enhanced pneumococcal adherence requires IgA1 protease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Lewis,et al.  Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia , 2002, The Pediatric infectious disease journal.

[8]  R. Adegbola,et al.  The pneumococcus: carriage, disease and conjugate vaccines. , 2002, Journal of medical microbiology.

[9]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[10]  R. Dagan,et al.  Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. , 2000, The Pediatric infectious disease journal.

[11]  R. Dagan,et al.  Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. , 2000, The Journal of infectious diseases.

[12]  M. Kazatchkine,et al.  An ELISA method to measure total and specific human secretory IgA subclasses based on selective degradation by IgA1-protease. , 2000, Journal of immunological methods.

[13]  A. Lucas,et al.  Avidity as a Determinant of the Protective Efficacy of Human Antibodies to Pneumococcal Capsular Polysaccharides , 1999, Infection and Immunity.

[14]  K. Bojang,et al.  Changes in the pattern of infant and childhood mortality in Upper River Division, The Gambia, from 1989 to 1993 , 1997, Tropical medicine & international health : TM & IH.

[15]  B. Greenwood,et al.  Nasopharyngeal carriage of pneumococci in Gambian children and in their families. , 1996, The Pediatric infectious disease journal.

[16]  B. Greenwood,et al.  Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. , 1996, Vaccine.

[17]  M. Kilian,et al.  Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence * , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  E. Tuomanen,et al.  Receptor specificity of adherence of Streptococcus pneumoniae to human type-II pneumocytes and vascular endothelial cells in vitro. , 1994, Microbial pathogenesis.

[19]  I. Jónsdóttir,et al.  Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. , 1994, The Journal of infectious diseases.

[20]  G. V. Van Hare,et al.  Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. , 1993, The Journal of pediatrics.

[21]  P. Brandtzaeg.  Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections. , 1992, The Journal of infectious diseases.

[22]  G. Rondini,et al.  IgG subclasses compared in maternal and cord serum and breast milk. , 1992, Archives of disease in childhood.

[23]  J. Mcghee,et al.  Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. , 1990, Journal of immunology.

[24]  J. Mestecky,et al.  Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. , 1988, Journal of immunology.

[25]  R. Austrian,et al.  Some aspects of the pneumococcal carrier state. , 1986, The Journal of antimicrobial chemotherapy.

[26]  G. R. Pullen,et al.  Antibody avidity determination by ELISA using thiocyanate elution. , 1986, Journal of immunological methods.

[27]  M. Sande,et al.  Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. , 1975, The Journal of infectious diseases.

[28]  J. Koplan.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[29]  Etiology and clinical signs of serious infections in young infants in developing countries: a WHO collaborative study. , 1999, The Pediatric infectious disease journal.

[30]  S. Jaffar,et al.  Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia. , 1998, The Pediatric infectious disease journal.

[31]  T. Lagergård,et al.  Inhibition of attachment of Streptococcus pneumoniae and Haemophilus influenzae by human milk and receptor oligosaccharides. , 1986, The Journal of infectious diseases.